Alexandar Blazevski1, Matthijs J Scheltema2, Brian Yuen3, Natasha Masand4, Tuan V Nguyen5, Warick Delprado6, Ron Shnier7, Anne-Maree Haynes8, Thomas Cusick8, James Thompson9, Phillip Stricker9. 1. St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia. Electronic address: a.blazevski@garvan.org.au. 2. St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; Amsterdam UMC, Amsterdam, The Netherlands. 3. St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. 4. Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia. 5. Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia; School of Biomedical Engineering, University of Technology, Sydney, NSW, Australia. 6. Douglas Hanly Moir Pathology, Macquarie Park, NSW, Australia. 7. I-MED Radiology, Sydney, NSW, Australia. 8. Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. 9. St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW, Sydney, Australia.
Abstract
BACKGROUND: Focal irreversible electroporation (IRE) can be used to treat men with localised prostate cancer (PCa) with reduced impact on quality of life (QoL). OBJECTIVE: To assess oncological and functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: To report on a prospective database of patients undergoing primary IRE between February 2013 and August 2018. A minimum of 12-mo follow-up was available for 123 patients. Median follow-up was 36 mo (interquartile range [IQR] 24-52 mo). A total of 112 (91%) patients had National Comprehensive Cancer Network intermediate risk and 11 (9%) had low risk. A total of 12 (9.8%) had International Society of Urological Pathology (ISUP) grade 1, 88 (71.5%) had ISUP 2, and 23 (18.7%) had ISUP 3. INTERVENTION: Focal IRE ablation of PCa lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Follow-up involved serial prostate-specific antigen (PSA), multiparametric magnetic resonance imaging (mpMRI), and transperineal template mapping biopsy (TTMB) at 12 mo. Failure-free survival (FFS) was defined as progression to whole-gland or systemic treatment or metastasis/death. Functional outcomes were assessed. RESULTS AND LIMITATIONS: Median age was 68yr (IQR 62-73yr). Median preoperative PSA was 5.7ng/ml (IQR 3.8-8.0ng/ml). On post-treatment TTMB, in-field recurrence was present in 2.7-9.8% of patients. FFS at 3yr was 96.75%, metastasis-free survival 99%, and overall survival 100%. A total of 18 patients required salvage treatment (12 had repeat IRE; six had whole-gland treatment). The negative predictive value of mpMRI was 94% and sensitivity 40% for detecting in-field residual disease 6 mo after treatment. Among patients who returned questionnaires, 80/81 (98.8%) remained pad free and 40/53 (76%) had no change in erectile function. CONCLUSIONS: Focal IRE in select patients with localised clinically significant PCa has satisfactory short-term oncological outcomes with a minimal impact on patient QoL. PATIENT SUMMARY: In this study, 123 patients underwent focal therapy using irreversible electroporation. Follow-up biopsy was clear of residual disease in 90.2-97.3% of patients. Of patients, 96.75% avoided whole gland treatment at 3yr. Crown
BACKGROUND: Focal irreversible electroporation (IRE) can be used to treat men with localised prostate cancer (PCa) with reduced impact on quality of life (QoL). OBJECTIVE: To assess oncological and functional outcomes. DESIGN, SETTING, AND PARTICIPANTS: To report on a prospective database of patients undergoing primary IRE between February 2013 and August 2018. A minimum of 12-mo follow-up was available for 123 patients. Median follow-up was 36 mo (interquartile range [IQR] 24-52 mo). A total of 112 (91%) patients had National Comprehensive Cancer Network intermediate risk and 11 (9%) had low risk. A total of 12 (9.8%) had International Society of Urological Pathology (ISUP) grade 1, 88 (71.5%) had ISUP 2, and 23 (18.7%) had ISUP 3. INTERVENTION: Focal IRE ablation of PCa lesions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Follow-up involved serial prostate-specific antigen (PSA), multiparametric magnetic resonance imaging (mpMRI), and transperineal template mapping biopsy (TTMB) at 12 mo. Failure-free survival (FFS) was defined as progression to whole-gland or systemic treatment or metastasis/death. Functional outcomes were assessed. RESULTS AND LIMITATIONS: Median age was 68yr (IQR 62-73yr). Median preoperative PSA was 5.7ng/ml (IQR 3.8-8.0ng/ml). On post-treatment TTMB, in-field recurrence was present in 2.7-9.8% of patients. FFS at 3yr was 96.75%, metastasis-free survival 99%, and overall survival 100%. A total of 18 patients required salvage treatment (12 had repeat IRE; six had whole-gland treatment). The negative predictive value of mpMRI was 94% and sensitivity 40% for detecting in-field residual disease 6 mo after treatment. Among patients who returned questionnaires, 80/81 (98.8%) remained pad free and 40/53 (76%) had no change in erectile function. CONCLUSIONS: Focal IRE in select patients with localised clinically significant PCa has satisfactory short-term oncological outcomes with a minimal impact on patient QoL. PATIENT SUMMARY: In this study, 123 patients underwent focal therapy using irreversible electroporation. Follow-up biopsy was clear of residual disease in 90.2-97.3% of patients. Of patients, 96.75% avoided whole gland treatment at 3yr. Crown
Authors: Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas Journal: Turk J Urol Date: 2020-10-09
Authors: Rafael R Tourinho-Barbosa; Bradford J Wood; Andre Luis Abreu; Bruno Nahar; Toshitaka Shin; Selcuk Guven; Thomas J Polascik Journal: World J Urol Date: 2020-05-22 Impact factor: 4.226
Authors: Alex Z Wang; Amir H Lebastchi; Luke P O'Connor; Michael Ahdoot; Sherif Mehralivand; Nitin Yerram; Samir S Taneja; Arvin K George; Rafael Sanchez-Salas; John F Ward; Pilar Laguna; Jean de la Rosette; Peter A Pinto Journal: World J Urol Date: 2021-01-02 Impact factor: 4.226
Authors: Han Jo Jeon; Hyuk Soon Choi; Bora Keum; Eun Joo Bang; Kang Won Lee; Sang Hyun Kim; Sun Young Yim; Jae Min Lee; Eun Sun Kim; Yeon Seok Seo; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Hong Bae Kim; Jong Hyuk Kim Journal: Sci Rep Date: 2021-07-28 Impact factor: 4.379